Business Context and Reporting Period
Lifemd, Inc. (LFMD) filed a Current Report on Form 8-K on March 9, 2026. The filing announces the release of financial results for the three months and full year ended December 31, 2025, along with earnings guidance for 2026. The company operates on The Nasdaq Global Market with common stock (LFMD) and 8.875% Series A Cumulative Perpetual Preferred Stock (LFMDP).
Key Financial Metrics
The provided 8-K filing text serves as a cover document referencing a press release (Exhibit 99.1) and investor presentation (Exhibit 99.2). The filing text itself does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. Investors must refer to the attached exhibits for detailed financial data.
Material Changes
The filing does not explicitly detail material changes versus prior periods within the text body. It indicates that such comparisons are contained within the press release and investor presentation furnished as exhibits.
Guidance, Outlook, and Risks
- Guidance: The company issued earnings guidance for the 2026 fiscal year, though specific targets are not listed in this text.
- Forward-Looking Statements: The filing includes standard cautionary notes regarding forward-looking statements, noting that actual results may differ materially due to risks and uncertainties.
- Regulation FD: The company furnished an investor presentation intended for use with analysts and investors, clarifying that this information is summary in nature and not deemed "filed" for liability purposes under Section 18 of the Exchange Act.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific revenue, net income, and cash flow figures for Q4 and FY 2025.
- Examine Exhibit 99.2 (Investor Presentation) for detailed 2026 earnings guidance and strategic outlook.
- Verify the status of the 8.875% Series A Cumulative Perpetual Preferred Stock (LFMDP) and any associated dividend obligations.
- Assess the risk factors detailed in the company's most recent 10-K or 10-Q filings referenced in the forward-looking statement disclaimer.